Pravastatin For The Treatment Of Preterm Labour, A Pilot Study
Preterm birth contributes to around 11% of all births worldwide and is the major cause of infant morbidity and mortality. Whilst in the UK survival of babies born preterm has improved, the proportion of survivors without long term developmental problems has not, and current treatments are ineffective at preventing this. This study aims to see whether women in preterm labour would be willing to be randomised to take a tablet (pravastatin) or placebo. Preterm labour is known to be due to both inflammation within the womb and contractions. Pravastatin in an anti-inflammatory agent which has been used safely in pregnancy, and which appears in in animal studies to reduce preterm labour associated events.
We hope if women are willing to accept this trial and participate, this will help us develop a larger clinical study to find a new treatment for preterm labour.
Chief Investigator: Professor Jane Norman
Number and location of participating sites / geographical scope (by region/ country): UK Single Site; aim to include second UK site in January 2019
EudraCT number: 2017-005021-21
Start and End date
Of grant award August 2018 – July 2020
Status: Currently recruiting
If you have participated in this study and would like to read how the study complies with GDPR, please click on this link:
Sponsor: ACCORD http://accord.scot/
Chief Investigator: Professor Jane Norman, QMRI; email@example.com
Trial Manager: Sonia Whyte
Clinical Research Fellow: Dr Eleanor Whitaker; firstname.lastname@example.org 0131 2426613
ECTU involvement: Statistics, database and randomisation service